Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Sharma

Showing results (301-310 of 353) with videos related to

Pageof 36
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 1, 2019
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to LorlatinibGeeta G Sharma, Diego Cortinovis, Francesco Agustoni, et al.
Cancer Research|October 17, 2018
Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven CancerSara Redaelli, Monica Ceccon, Marina Zappa, et al.
Molecular and Cellular Biology|June 1, 2005
Involvement of human MOF in ATM functionArun Gupta, Girdhar G Sharma, Charles S H Young, et al.
Molecular and Cellular Biology|May 19, 2010
MOF and histone H4 acetylation at lysine 16 are critical for DNA damage response and double-strand break repairGirdhar G Sharma, Sairei So, Arun Gupta, et al.
Optics Express|June 10, 2009
Terahertz pulse induced intervalley scattering in photoexcited GaAsF H Su, F Blanchard, G Sharma, et al.
American Journal of Hematology|August 19, 2020
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma relapsed/refractory to chemotherapyElisa Bossi, Andrea Aroldi, Filippo A Brioschi, et al.
Future Oncology (London, England)|August 18, 2023
The MOTION study: a randomized, phase III study of vimseltinib for the treatment of tenosynovial giant cell tumorWilliam D Tap, Maitreyi G Sharma, Marc Vallee, et al.
Kidney International|August 24, 2020
NELL1 is a target antigen in malignancy-associated membranous nephropathyTiffany N Caza, Samar I Hassen, Zeljko Dvanajscak, et al.
JAMA|January 10, 2001
Fludrocortisone acetate to treat neurally mediated hypotension in chronic fatigue syndrome: a randomized controlled trialP C Rowe, H Calkins, K DeBusk, et al.
Research in Veterinary Science|June 5, 2007
Evaluation of indigenous milk ELISA with m-culture and m-PCR for the diagnosis of bovine Johne's disease (BJD) in lactating Indian dairy cattleG Sharma, S V Singh, I Sevilla, et al.
Pageof 36

Showing results (301-310 of 353) with videos related to

Sort By:
Pageof 36
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 1, 2019
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to LorlatinibGeeta G Sharma, Diego Cortinovis, Francesco Agustoni, et al.
Cancer Research|October 17, 2018
Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven CancerSara Redaelli, Monica Ceccon, Marina Zappa, et al.
Molecular and Cellular Biology|June 1, 2005
Involvement of human MOF in ATM functionArun Gupta, Girdhar G Sharma, Charles S H Young, et al.
Molecular and Cellular Biology|May 19, 2010
MOF and histone H4 acetylation at lysine 16 are critical for DNA damage response and double-strand break repairGirdhar G Sharma, Sairei So, Arun Gupta, et al.
Optics Express|June 10, 2009
Terahertz pulse induced intervalley scattering in photoexcited GaAsF H Su, F Blanchard, G Sharma, et al.
American Journal of Hematology|August 19, 2020
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma relapsed/refractory to chemotherapyElisa Bossi, Andrea Aroldi, Filippo A Brioschi, et al.
Future Oncology (London, England)|August 18, 2023
The MOTION study: a randomized, phase III study of vimseltinib for the treatment of tenosynovial giant cell tumorWilliam D Tap, Maitreyi G Sharma, Marc Vallee, et al.
Kidney International|August 24, 2020
NELL1 is a target antigen in malignancy-associated membranous nephropathyTiffany N Caza, Samar I Hassen, Zeljko Dvanajscak, et al.
JAMA|January 10, 2001
Fludrocortisone acetate to treat neurally mediated hypotension in chronic fatigue syndrome: a randomized controlled trialP C Rowe, H Calkins, K DeBusk, et al.
Research in Veterinary Science|June 5, 2007
Evaluation of indigenous milk ELISA with m-culture and m-PCR for the diagnosis of bovine Johne's disease (BJD) in lactating Indian dairy cattleG Sharma, S V Singh, I Sevilla, et al.
Pageof 36